RxDoctor Payments Data

Ali Enayati

Internal Medicine · Los Angeles, CANPI 1043269194

Payments from drug & device makers

$4,213in general payments, 2019–2025

Across 178 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$717
  • Lilly USA, LLC$439
  • Amgen$390
  • Gilead$277
  • AstraZeneca$232
  • Pfizer$191
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,17499%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,213 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$3,336,095
Medicare patients
650
Services billed
29,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide409$446,464
EliquisApixaban100$76,417
FarxigaDapagliflozin Propanediol69$70,948
OzempicSemaglutide62$57,178
WegovySemaglutide35$48,142
LinzessLinaclotide51$44,725
GemtesaVibegron43$40,977
JardianceEmpagliflozin44$30,598
Repatha SureclickEvolocumab26$27,169
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$26,323
Repatha SyringeEvolocumab27$20,805
Praluent PenAlirocumab29$16,949
Nurtec OdtRimegepant Sulfate11$15,267
TrintellixVortioxetine Hydrobromide22$14,811
EntrestoSacubitril/Valsartan15$13,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$439$446,464409 claims
Novo NordiskOzempic, Wegovy$169$105,32097 claims
PfizerEliquis, Nurtec Odt, Paxlovid, Prempro$191$100,366170 claims
AstraZenecaFarxiga$232$70,94869 claims
AbbVieLinzess, Synthroid$717$52,432148 claims
Sumitomo Pharma America, Inc.Gemtesa$26$40,97743 claims
Boehringer IngelheimJardiance$169$30,59844 claims
GSKTrelegy Ellipta$100$26,32336 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$174$14,81122 claims
NovartisEntresto$97$13,31015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →